Bausch Health Companies Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Bausch Health Companies Inc. (BHC) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $491.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2017-03-01
- Bausch Health Companies Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $491.00M, a 3.16% decline from fiscal 2015.
- Bausch Health Companies Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $507.00M, a 32.72% increase from fiscal 2014.
- Bausch Health Companies Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $382.00M, a 8.18% increase from fiscal 2013.
- Bausch Health Companies Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $353.10M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2016-12-31 | $491.00M 10-K · filed 2017-03-01 | |
| 2015-12-31 | $507.00M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $382.00M 10-K · filed 2016-04-29 | $381.60M 10-K · filed 2015-02-25 |
| 2013-12-31 | $353.10M 10-K · filed 2015-02-25 | |
| 2012-12-31 | -$4.20M 10-K · filed 2014-02-28 | |
| 2011-12-31 | -$57.70M 10-K · filed 2013-02-28 | |
| 2010-12-31 | $32.40M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |